“The R&D tax incentive provides significant leverage to the Pharmaxis research team’s development of new drugs for inflammation and fibrotic diseases," said CEO Gary Phillips.

Clinical stage cannabinoid company Botanix Pharmaceuticals (ASX:BOT) has been awarded a new Innovation Connections Grant by federal agency AusIndustry.

It was with sadness that AusBitoech acknowledges the passing of Dr John Holaday (1945-2019).

Australian biopharmaceutical company Opthea (ASX:OPT) has announced the presentation of additional data from the recently completed 366 patient Phase 2b randomised controlled wet AMD study of OPT-302 with Novartis' PBS-listed LUCENTIS (ranibizumab) compared to LUCENTIS alone.

"Breakthroughs in this area will provide significant benefits to the medical treatment Australians receive as well as providing new business opportunities," said education minister Dan Tehan.

Two Australian scientists have each been awarded five year $1.25 million CSL Centenary Fellowships for research looking at ways to improve treatments for two of the world’s biggest health challenges - malaria and cancer.